Skip to main content
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. — Investor Relations & Filings

Ticker · CUE ISIN · US22978P1066 LEI · 549300PBW78KZA33WC97 US Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2026-06-02 Board/Management Inform…
Country US United States of America
Listing US CUE

About Cue Biopharma, Inc.

https://www.cuebiopharma.com/

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable, engineered biologics to selectively modulate the human immune system. The company's proprietary platform creates therapeutics designed to mimic natural immune signals to precisely engage, expand, and activate specific, disease-relevant T cells. This targeted approach is being applied to develop immunotherapies for the treatment of cancer and autoimmune diseases, with the goal of restoring immune balance and providing effective treatments for serious conditions.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 88% confidence The document is a Form 8-K “Current Report” filed under the Exchange Act that discloses Item 5.02 (Departure and Election of Directors and Officers) and Item 8.01 (Other Events). All disclosures pertain to resignations of board members and appointments of new directors and senior officers (Chief Legal & Compliance Officer, Corporate Secretary, Principal Accounting Officer, etc.). There are no financial statements or earnings data, nor is it an invitation or proxy. This is a clear example of an announcement of changes in the company’s board of directors and senior management, which maps to “Board/Management Information.”
2026-06-02 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-21 English
8-K
Regulatory Filings
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cue Biopharma, Inc. dated April 22, 2026. It reports a material corporate event: a 1-for-30 reverse stock split of the company's common stock, effective April 23, 2026. The document includes details about the reverse stock split, its purpose (to comply with Nasdaq listing requirements), adjustments to stock options and warrants, and trading information post-split. It also references the company's proxy statement and includes a Certificate of Amendment as an exhibit. The Form 8-K is a regulatory filing used to announce major corporate events and changes that shareholders should know about. This document is not a full financial report, earnings release, or management discussion, but rather a specific announcement of a capital structure change. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8972 characters) and content confirm it is a substantive filing, not a brief announcement or certification. Confidence is high due to clear identification of the reverse stock split event and related capital structure changes.
2026-04-22 English
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Cue Biopharma, Inc. It reports the certified results of the 2026 annual meeting of stockholders, including election of directors, ratification of auditors, approval of executive compensation, and approval of a reverse stock split. The key section is Item 5.07, which is specifically about submission of matters to a vote of security holders. The document contains detailed voting results from the annual meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an Annual Report, Audit Report, or Management Report, nor is it a Proxy Statement or AGM Information. It is a formal announcement of voting results from the AGM. The length (5432 characters) and content confirm it is the voting results announcement itself, not just a notice or proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2026-04-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.